FDA approves Gilead's HCV treatment as 2nd line therapy — 4 insights

The FDA approved Gilead Sciences' Vosevi as a second line therapy for chronic hepatitis C.

Here's what you should know:

1. Vosevi is a fixed-dose, combination tablet which consists of sofosbuvir, velpatasvir and voxilaprevir. All three drugs are FDA approved.

2. According to a release, this is the first treatment for patients who previously used a direct-acting antiviral for HCV.

3. Vosevi is an option for patients who did not have success with a direct-acting agent.

4. Gilead's President and CEO John Milligan said in a release, "The evolution of Gilead’s portfolio of HCV single-tablet regimens has been driven by our commitment to address previously unmet needs and put the possibility of cure within reach for as many HCV patient populations as possible."
http://www.gilead.com/news/press-releases/2017/7/us-food-and-drug-administration-approves-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-retreatment-of-adults-with-chronic-hepatitis-c-virus

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast